Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL30372129 | 1.00 | LMNA (0.33) | LMNATDP1 | |
| Potassium Ion SCHEMBL560059 | 0.96 | LMNA (0.32) | LMNATDP1 | |
| Potassium Ion SCHEMBL29713986 | 0.96 | LMNA (0.32) | LMNATDP1 | |
| SCHEMBL42027 | 0.94 | LMNA (0.35) | LMNATDP1 | |
| SCHEMBL2721462 | 0.81 | CYP26B1 (0.34) | LMNATDP1 | |
| SCHEMBL136845 | 0.81 | RXRA (0.31) | — | |
| SCHEMBL114709 | 0.81 | RXRA (0.31) | — | |
| Potassium Ion SCHEMBL3791274 | 0.81 | LMNA (0.31) | LMNATDP1 | |
| Potassium SCHEMBL9929144 | 0.80 | RXRA (0.30) | — | |
| SCHEMBL9929142 | 0.80 | RXRA (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053222-B2 | Fluorescent compounds | PIERCE BIOTECHNOLOGY, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-10696653-B2 | Cyanine compounds | PIERCE BIOTECHNOLOGY, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10351551-B2 | Fluorescent compounds | PIERCE BIOTECHNOLOGY, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| EP-3081564-B1 | INDOLE DERIVATIVES AS LABELING DYE FOR BIOMOLECULE | PIERCE BIOTECHNOLOGY INC (US) | 2019-07-10 | — | — | EP | disclosed |
| US-20180327387-A1 | Cyanine Compounds | PIERCE BIOTECHNOLOGY, INC. (US) | 2018-11-15 | — | — | US | disclosed |
| US-10053447-B2 | Fluorescent compounds | PIERCE BIOTECHNOLOGY, INC (US) | 2018-08-21 | — | — | US | disclosed |
| EP-3029027-B1 | FLUORESCENT COMPOUNDS | PIERCE BIOTECHNOLOGY INC (US) | 2018-06-27 | — | — | EP | disclosed |
| US-10000467-B2 | Cyanine compounds | PIERCE BIOTECHNOLOGY, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20180118723-A1 | FLUORESCENT COMPOUNDS | PIERCE BIOTECHNOLOGY, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20170158858-A9 | CYANINE COMPOUNDS | PIERCE BIOTECHNOLOGY, INC. | 2017-06-08 | — | — | US | disclosed |
| US-8889884-B1 | Phosphine derivatives of fluorescent compounds | PIERCE BIOTECHNOLOGY, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140255312-A1 | CYANINE COMPOUNDS | PIERCE BIOTECHNOLOGY, INC. | 2014-09-11 | — | — | US | disclosed |
| US-20140072515-A9 | CYANINE COMPOUNDS | PIERCE BIOTECHNOLOGY, INC. | 2014-03-13 | — | — | US | disclosed |
| EP-2655327-A1 | FLUORESCENT COMPOUNDS | Pierce Biotechnology, Inc. (US) | 2013-10-30 | — | — | EP | disclosed |
| US-20130251637-A9 | FLUORESCENT COMPOUNDS | DYOMICS GMBH (DE) | 2013-09-26 | — | — | US | disclosed |
| WO-2013130761-A1 | INDOLE DERIVATIVES AS LABELING DYE FOR BIOMOLECULE | PIERCE BIOTECHNOLOGY, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| US-20130230466-A1 | CYANINE COMPOUNDS | HERMANSON GREG (US) | 2013-09-05 | — | — | US | disclosed |
| US-20120294807-A9 | FLUORESCENT COMPOUNDS | DYOMICS GMBH (DE) | 2012-11-22 | — | — | US | disclosed |
| WO-2012088007-A1 | FLUORESCENT COMPOUNDS | PIERCE BIOTECHNOLOGY, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120156140-A1 | FLUORESCENT COMPOUNDS | DYOMICS GMBH (DE) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158858-A9 | CYANINE COMPOUNDS | NCL, NOP58, NAT10 | LMNA 836/4885TDP1 563/4885 |
| US-20180118723-A1 | FLUORESCENT COMPOUNDS | NCL, FUS, EFTUD2 | LMNA 512/4885TDP1 654/4885 |
| US-10351551-B2 | Fluorescent compounds | NCL, FUS, EFTUD2 | LMNA 512/4885TDP1 654/4885 |
| US-20180327387-A1 | Cyanine Compounds | NCL, NOP58, NAT10 | LMNA 836/4885TDP1 563/4885 |
| US-20140255312-A1 | CYANINE COMPOUNDS | NCL, NOP58, NAT10 | LMNA 836/4885TDP1 563/4885 |
| US-20120156140-A1 | FLUORESCENT COMPOUNDS | NCL, FUS, EFTUD2 | LMNA 512/4885TDP1 654/4885 |
| US-10696653-B2 | Cyanine compounds | NCL, NOP58, NAT10 | LMNA 836/4885TDP1 563/4885 |
| US-20130230466-A1 | CYANINE COMPOUNDS | NCL, NOP58, NAT10 | LMNA 836/4885TDP1 563/4885 |
| US-11053222-B2 | Fluorescent compounds | NCL, FUS, EFTUD2 | LMNA 512/4885TDP1 654/4885 |
| US-20130251637-A9 | FLUORESCENT COMPOUNDS | NCL, FUS, EFTUD2 | LMNA 512/4885TDP1 654/4885 |
| US-10000467-B2 | Cyanine compounds | NCL, NOP58, NAT10 | LMNA 836/4885TDP1 563/4885 |
| US-10053447-B2 | Fluorescent compounds | NCL, FUS, EFTUD2 | LMNA 512/4885TDP1 654/4885 |
| US-20120294807-A9 | FLUORESCENT COMPOUNDS | NCL, FUS, EFTUD2 | LMNA 512/4885TDP1 654/4885 |
| US-20140072515-A9 | CYANINE COMPOUNDS | NCL, NOP58, NAT10 | LMNA 836/4885TDP1 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.